220 results about "Virus strain" patented technology

The invention discloses an hMPV virus fusion protein F variant, an mRNA vaccine and application of the hMPV virus fusion protein F variant and the mRNA vaccine. The hMPV fusion protein F variant has amino acid residue difference on one or more sites relative to an hMPV fusion protein F with the login number of AGJ74096.1 in a GeneBank database, wherein the amino acid sequence of the hMPV fusion protein F variant is shown as SEQ ID NO: 1 or SEQ ID NO: 2. The mRNA vaccine designed based on the hMPV fusion protein F variant can induce a strong specific antibody reaction, the durability of the antibody in vivo is strong, the induced antibody can well neutralize an hMPV strain, the amplification of the hMPV in the lung is controlled, and the immune response of the hMPV in the lung is inhibited. Therefore, the specific antibody induced by the mRNA vaccine provides an effective basis for preventing hMPV virus infection related diseases and developing multi-combined vaccines.

The invention discloses a separation method of a bovine ephemeral fever virus, the obtained bovine ephemeral fever virus and application of the bovine ephemeral fever virus. Belongs to the technical field of bovine ephemeral fever virus separation. The invention aims to provide an efficient and rapid method for separating the bovine ephemeral fever virus. The invention provides a method for separating bovine ephemeral fever virus, which comprises the following steps: inoculating a bovine anticoagulant sample to KC cells for culture, harvesting virus, inoculating to grow into monolayer BHK-21 cells, and carrying out passage to obtain passage cells with cytopathy of the first generation; the virus strain can also be used for screening, preparing and detecting a bovine ephemeral fever virus antibody and preparing a bovine ephemeral fever virus infected animal model.

The invention belongs to the field of veterinary biotechnology detection, and particularly relates to a hybridoma cell strain and a monoclonal antibody for detecting or identifying MDV-1 and application of the hybridoma cell strain and the monoclonal antibody. The hybridoma cell strain MDV-1Mab-pp38-E2 is obtained through screening by taking pp38 protein of MDV-1 as immunogen, the preservation number is CCTCC NO: C202501, the monoclonal antibody generated by the hybridoma cell strain can recognize I-type chicken Marek's disease virus strains with different serum, and the monoclonal antibody can be used for identifying the type I chicken Marek's disease virus strains with different serum types. The kit has good specificity and sensitivity and can be used for exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines without cross reaction with serum type II chicken Marek's disease virus, serum type III chicken Marek's disease virus, chicken egg drop syndrome virus (EDSV) and other common poultry disease viruses, and the kit has good specificity and sensitivity and can be applied to exogenous virus detection of the serum type I chicken Marek's disease virus in poultry virus live vaccines. The kit can also be used for clinical identification, virus content determination and epidemiological investigation of serotype I chicken Marek's disease virus.

The invention relates to the technical field of biological medicine, in particular to a hepatitis A inactivated vaccine and a preparation method thereof. Comprising the following steps: cell amplification, virus culture, virus harvesting, cell disruption, ultrafiltration concentration, inactivation, purification and finished product obtaining. The virus culture comprises the following steps: separating from excrement of a hepatitis A patient and carrying out adaptive passage to obtain a virus strain; adding a carrier into a bioreactor, sterilizing for later use, inoculating a virus strain into a collected cell suspension, and transferring into the bioreactor for culturing; the cell disruption step comprises the following steps: carrying out ultrasonic oscillation on a collected virus harvesting liquid to obtain a cell disruption liquid; trichloromethane is added for extraction and centrifugation, and supernatant virus liquid is collected; the invention provides a preparation method of a hepatitis A inactivated vaccine, which is used for preparing the efficient, safe and stable hepatitis A inactivated vaccine by optimizing virus culture and inactivation processes. The method has the advantages of high virus yield and low production cost, and is suitable for large-scale production and application.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

The invention discloses a Newcastle disease vaccine strain with high antibody escape ability and a modification method thereof, the cell strain is preserved in China General Microbiological Culture Collection Center on January 19, 2024, the address of the preservation unit is CGMCC No.45870, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the classification name of the strain is Newcastle disease virus strain. The recombinant NDV vaccine strain has the same antigen site as the current NDV gene VII type epidemic strain and has the efficient proliferation efficiency superior to that of a classical vaccine strain La Sota, the thermal stability of the NDV vaccine strain is improved by the constructed recombinant vaccine strain, and the cost of vaccine cold-chain transportation is reduced.

The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.

The application discloses a disease transmission link prediction method and system based on a dynamic hypergraph neural network, aiming to comprehensively depict virus transmission paths and risk levels from multiple dimensions. First, data is collected from a gene database, mobile device logs and clinical texts, virus variation characteristics, population contact relationships and symptom semantic information are extracted respectively, and a dynamic hypergraph that integrates virus strain nodes, individual nodes and regional nodes is constructed. The hyperedge is defined according to molecular similarity, space-time contact and semantic overlap, and the weight is dynamically adjusted according to the transmission intensity of the infectious disease. A multi-modal hypergraph neural network with variation perception is introduced to jointly model and adaptively fuse multiple types of hyperedges and multi-scale features, output node propagation embedding vectors and predict potential transmission chains, perform prevention and control responses, and realize real-time deployment and feedback loop in an edge-cloud collaborative manner, ensuring efficient and accurate infectious disease transmission modeling and intervention control while ensuring data privacy.

The invention relates to the technical field of viruses, in particular to a construction method and application of an African swine fever virus strain. According to the invention, the three virulence genes MGF110-9L, EP402R and I73R of the African swine fever virus are taken as targets for the first time to construct a virus strain with deletion of the three virulence genes, and the virus strain is found to be capable of effectively reducing the virus toxicity but retaining better immunogenicity, can improve the immunity of an organism to the African swine fever virus, and has a relatively great application prospect.

The invention discloses a disease transmission link prediction method and system based on a dynamic hypergraph neural network, and aims to comprehensively describe a virus transmission path and a risk level from multiple dimensions. The method comprises the following steps: firstly, collecting data from a gene database, a mobile equipment log and a clinical text, respectively extracting virus variation characteristics, a crowd contact relationship and symptom semantic information, and constructing a dynamic hypergraph fusing virus strain nodes, individual nodes and region nodes; the hyperedge is defined according to molecular similarity, space-time contact and semantic overlap, and the weight is dynamically adjusted along with the infectious disease transmission intensity. A multi-modal hypergraph neural network of variation perception is introduced, joint modeling and adaptive fusion are performed on multi-type hyperedge and multi-scale features, a node propagation embedded vector is output, a potential propagation chain is predicted, prevention and control response is executed, and real-time deployment and feedback closed loop are realized in an edge-cloud cooperation mode. And efficient and accurate infectious disease transmission modeling and intervention control are completed on the premise of ensuring data privacy.

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

This document provides details regarding the construction of a recombinant African swine fever virus (ASFV) live attenuated vaccine for the prevention of African swine fever (ASF) caused by various viral strains of ASFV such as the highly virulent Georgia 2007 isolate (“ASFV-G”). Exemplary vaccines comprise an ASFV-GΔI177l modified virus, i.e., a recombinant ASFV-G modified by deletion of a portion of the I177L ORF such that the I177L gene is rendered non-functional.

The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.

The invention provides an L protein mutated recombinant foot-and-mouth disease virus strain and application thereof in vaccine preparation, and belongs to the technical field of biological medicine. Firstly, it is found that overexpression of CISD2 protein in host cells can inhibit FMDV replication, and an inhibition mechanism is analyzed, specifically, the CISD2 inhibits FMDV replication by inhibiting expression of L protein, especially inducing degradation of the L protein through a proteasome pathway. The invention also identifies a key site for degrading the L protein by the CISD2 protein, the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein is successfully constructed and rescued by introducing amino acid mutation of the key site into the L protein by utilizing a reverse genetic technology, the capabilities of degrading the L protein and inhibiting FMDV replication by the CISD2 protein are eliminated, the virus titer is improved, and the recombinant foot-and-mouth disease virus can be used for preparing the recombinant foot-and-mouth disease virus with the mutated key amino acid site of the L protein. The strain has good production performance and can be used for preparing recombinant foot-and-mouth disease virus strains and recombinant vaccine strains.

The invention relates to the technical field of biological detection, and particularly discloses an ELISA kit for detecting a neutralizing antibody of a severe fever with thrombocytopenia syndrome virus and an application method of the ELISA kit. The ELISA kit comprises an ELISA plate on which SFTSV receptor LRP1 protein is fixed, and an enzyme-labeled SFTSV Gn-8M, wherein the SFTSV receptor LRP1 protein is fixed on the ELISA plate; the SFTSV Gn-8M is an SFTSV membrane protein Gn mutant designed by the invention, and can be specifically combined with an SFTSV receptor LRP1 protein on an elisa plate, and compared with a standard virus strain Gn protein, the self-designed SFTSV Gn-8M has amino acid mutation of eight sites, has stronger combining capacity with a host cell receptor, and can be used for detecting the SFTSV. The kit disclosed by the invention has the characteristics of high safety, high efficiency, high flux, high specificity, high sensitivity, high stability and the like, and is suitable for large-scale rapid screening of the neutralizing antibody of the severe fever with thrombocytopenia syndrome virus.

The invention belongs to the field of veterinary biological products, and relates to a porcine reproductive and respiratory syndrome virus strain and application thereof. The invention particularly discloses a porcine reproductive and respiratory syndrome virus strain with a microbial preservation number of CGMCC (China General Microbiological Culture Collection Center) No.47095. The invention also discloses a vaccine composition prepared from the strain. After pigs are inoculated with the vaccine composition, the vaccine composition can resist challenge of a porcine reproductive and respiratory integrated virus SD strain and a porcine reproductive and respiratory integrated virus HuN4 strain, and has application prospects.

The present invention belongs to the field of biomedicine. Provided are an influenza nanoparticle vaccine, and a preparation method therefor and the use thereof. A fusion protein containing an influenza virus strain HA protein or a fragment thereof, an antigenic epitope of the influenza virus protein, and ferritin, as an antigen, can induce an immune response effect against an influenza virus, and a vaccine composed of the fusion protein and an MF59 adjuvant can induce a protection effect against viral challenge and have a good cross-protection effect.

The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain, which comprises a genome sequence shown in SEQ ID NO: 1. The attenuated strain comprises one or more genetic modifications of the sequence SEQ ID NO: 1, and the genetic modifications reduce the virulence of the strain.

The invention mainly relates to a bovine rotavirus inactivated vaccine and a preparation method thereof, and according to the preparation method of the bovine rotavirus inactivated vaccine, ultrasonic emulsification conditions are as follows: the ultrasonic frequency is 24-28 kHz, the power density is controlled within the range of 0.6-0.8 W / cm, the single pulse time is 8-12 seconds, the ultrasonic time is 60-120 seconds, ultrasonic emulsification is carried out in a refrigerant bath at the temperature of 2-5 DEG C, the temperature fluctuation is + / -0.5 DEG C, and the ultrasonic time is 60-120 seconds. The virus content in the inactivated vaccine is greater than or equal to 5 * 10 < 5.0 > TCID50 / ml, and the neutralizing antibody titer within 21-49 days after secondary immunization is greater than or equal to 900. The prepared bovine rotavirus inactivated vaccine is subjected to ultrasonic emulsification, a generated neutralizing antibody can completely neutralize an RVA / Bovine-tc / CHN / SHH2023001 / 2023 / G10P [11] virus strain, the titer is high (the titer can reach 1700 or above at most), the duration time is long, the G10P [11] type bovine rotavirus is the most common virus infected in a dairy cow group, and the G10P [11] type bovine rotavirus can be used for preparing the vaccine. Therefore, the vaccine can be used as an alternative vaccine for preventing calves from being infected with bovine rotavirus.

The application belongs to the technical field of biology, and discloses a kind of Myzus persicae densovirus, amplification and connector method and its application, Myzus persicae densovirus name is Myzus persicae densovirus 2, abbreviated as MpDV2, preserved in China typical culture preservation center, and the preservation number is V202281.The Myzus persicae densovirus MpDV2 provided in the application is a virus strain that has not been isolated and identified before and has pathogenicity to Myzus persicae, and the full-length sequence of the genome of the Myzus persicae densovirus MpDV2 (including the complete terminal inverted repeat sequence) is disclosed for the first time, and the influence of the virus infection on the growth and development of Myzus persicae and the population dynamics / growth.The Myzus persicae densovirus MpDV2 of the application significantly reduces the intrinsic growth rate (r), net reproduction rate (R0) and week-long growth rate (lambda) of Myzus persicae population, and prolongs the average generation time (T) of the population, and the MpDV2 infection has a significant influence on the growth and development of Myzus persicae and population growth.

The invention belongs to the field of veterinary virology, and discloses a bovine ephemeral fever virus strain and reverse genetic application thereof, and the reverse genetic steps are as follows: taking pCI plasmid as a skeleton to prepare plasmid for expressing a complete genome of bovine ephemeral fever virus; the method comprises the following steps: respectively preparing auxiliary plasmids for expressing an N protein gene, a P protein gene, an L protein gene and a G protein gene of the bovine ephemeral fever virus by taking pCAGGS plasmids as a skeleton, co-transfecting BHK-21 cells by using the five plasmids, and culturing the cells to obtain the rescued bovine ephemeral fever virus. The rescued bovine ephemeral fever virus has no obvious difference from the reproductive capacity of the parent virus, and the genome is still stable after 10 generations of continuous passage in BHK-21 cells. The invention provides methodological support for genetic modification of the bovine ephemeral fever virus, and has an application prospect.

The invention provides application of periplocin in preparation of anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drugs, and belongs to the technical field of antiviral drugs. Experimental results show that periplocin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the periplocin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention relates to a cherry valley duck PLV virus vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus immunity. The vaccine is prepared by taking a Parry's Lagon virus (PLV) virus strain PLV-20155 as an immunogen, the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.46296. The invention further discloses a preparation method of the vaccine. The vaccine is a PLV-20155 virus inactivated vaccine, and the preparation method of the vaccine comprises the following steps: inoculating the PLV-20155 virus into an SPF chick embryo for propagation, harvesting a virus liquid, inactivating with formaldehyde, verifying safety, emulsifying with white oil to prepare the vaccine and the like. In addition, the vaccine disclosed by the invention can be used for effectively preventing diseases such as laying rate reduction, follicle necrosis and fallopian tube atrophy of the cherry valley ducks caused by the PLV-20155 virus, and the economic benefit of breeding is remarkably improved.

This application belongs to the field of pharmaceutical technology. More specifically, it relates to the use of sodium metatungstate in the preparation of drugs for treating or preventing influenza virus infection. Experiments have shown that sodium metatungstate has a broad-spectrum anti-influenza virus effect and can effectively inhibit influenza virus strains of different serotypes such as H1N1 and H3N2 on cell models. In addition, it also has an inhibitory effect on oseltamivir-resistant virus strains. The study on the anti-influenza virus mechanism of sodium metatungstate found that sodium metatungstate does not directly inactivate influenza virus; although it causes agglutination of the virus during the virus adsorption process, it does not affect the occurrence of adsorption, nor does it affect the process of the virus being endocytosed into the cytoplasm. However, sodium metatungstate will block the nuclear entry of influenza virus vRNP, thereby inhibiting virus replication.

The invention uses ex vivo human airway cultures to assess the transmissibility and replication ability of influenza and coronavirus strains. By comparing the pandemic influenza A H1N1 and the highly pathogenic influenza A H5N1 as reference virus strains, the spreading risks of various viruses are evaluated and classified. In addition, an in vitro model is used to assess the degree of alveolar fluid clearance (AFC) impairment caused by the virus as an indicator of the severity of the disease. The research reveals the relevance among the virus replication ability, human transmission, AFC damage degree and clinical disease severity of different influenza and coronavirus strains in bronchus.

The invention discloses a preparation method of a DNA (deoxyribonucleic acid) vaccine for preventing canine distemper, which comprises the following steps: taking plasmids of genes containing a newly separated canine distemper virus strain, namely a canine distemper virus fusion protein with an amino acid sequence shown as SEQ ID NO.6 and / or a hemagglutinin protein with an amino acid sequence shown as SEQ ID NO.8 as immunogens; hUO, mPEG-DMG, distearoyl phosphatidylcholine and cholesterol are used as lipid materials to prepare the canine distemper lipid nanoparticle DNA vaccine, and the vaccine can effectively stimulate neutralizing antibodies of mice, dogs, foxes and raccoon dogs and has clinical practical prospects.

The invention provides a recombinant foot-and-mouth disease virus strain with high antigen yield as well as a construction method and application thereof, and belongs to the technical field of biology. The invention relates to a recombinant foot-and-mouth disease virus strain, wherein L protein is mutant L protein with 108th amino acid mutated or deleted. According to the invention, overexpression of host protein RAB20 inhibits replication of FMDV, and L protein is degraded through a proteasome pathway, so that virus replication is inhibited; a recombinant foot-and-mouth disease virus strain which is not inhibited by host protein RAB20 to replicate is constructed by mutating a key amino acid site (108) in FMDV L protein, the recombinant virus can be stably passaged, has the characteristic of high virus titer on BHK-21 cells, improves the virus titer and antigen yield, can be used for preparing FMDV vaccines, and can be used for preparing FMDV vaccines. Good application prospects are realized.

The present invention relates to the technical field of biomedicine, and specifically to an inactivated hepatitis A vaccine and a preparation method thereof. The steps include: cell amplification, virus culture, virus harvesting, cell disruption, ultrafiltration concentration, inactivation, purification, and finished product; the virus culture step is: isolating from the feces of hepatitis A patients and obtaining virus strains through adaptive passage; adding a carrier to the bioreactor for sterilization and standby use, inoculating the virus strain into the collected cell suspension and transferring it to the bioreactor for culture; the cell disruption step is: ultrasonically vibrating the collected virus harvest liquid to obtain a cell disruption liquid; adding chloroform for extraction, centrifuging, and collecting the supernatant virus liquid. The present invention provides a preparation method for an inactivated hepatitis A vaccine, which prepares an efficient, safe, and stable inactivated hepatitis A vaccine by optimizing the virus culture and inactivation process. The method has the advantages of high virus yield and low production cost, and is suitable for large-scale production and application.

The invention belongs to the technical field of virus and gene engineering, and particularly relates to an expression vector of a respiratory syncytial virus (RSV) ON1 genotype consensus sequence strain and an editing strain, a reverse genetic manipulation system and an application of the reverse genetic manipulation system of the respiratory syncytial virus ON1 genotype consensus sequence strain and the editing strain of the RSV ON1 genotype consensus sequence strain and the editing strain of the respiratory syncytial virus ON1 genotype consensus sequence strain. According to the invention, an RSV-ON1 genotype consensus sequence strain is firstly constructed and saved, on the basis, 72 nucleotides which are repeatedly inserted into a G gene of the consensus sequence strain are removed through a gene editing technology, and two strains with different virus G gene sequences are obtained. According to the invention, through construction of RSV infectious clone edited by RSV-ON1 genotype G gene and rescue of the two strains, a fast, simple and accurate RSV reverse genetic system is constructed, and the RSV reverse genetic system can be applied to research on RSV in-vitro virus replication mechanism and pathogenesis and neutralizing antibody immune escape. A etiological technical platform is provided for research, development and evaluation of RSV vaccines, antibodies, drugs and the like.